Insmed Incorporated (NASDAQ:INSM) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in shares of Insmed Incorporated (NASDAQ:INSM) by 3.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 140,915 shares of the biopharmaceutical company’s stock after selling 5,761 shares during the period. Segall Bryant & Hamill LLC’s holdings in Insmed were worth $10,287,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in Insmed by 15,915.2% in the 1st quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 21,963 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in Insmed by 1.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 38,232 shares of the biopharmaceutical company’s stock valued at $1,037,000 after purchasing an additional 610 shares in the last quarter. Vanguard Group Inc. increased its holdings in Insmed by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock worth $393,636,000 after purchasing an additional 383,714 shares during the last quarter. Natixis acquired a new position in shares of Insmed in the 1st quarter valued at approximately $191,000. Finally, Shell Asset Management Co. purchased a new position in shares of Insmed during the 1st quarter valued at approximately $412,000.

Insmed Price Performance

NASDAQ:INSM opened at $73.81 on Friday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The business’s 50-day moving average price is $72.07 and its 200 day moving average price is $65.65. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The firm has a market cap of $13.20 billion, a P/E ratio of -13.30 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the prior year, the company earned ($1.10) earnings per share. Insmed’s revenue was up 18.1% on a year-over-year basis. As a group, sell-side analysts predict that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. This represents a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on INSM shares. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a research note on Thursday, October 3rd. UBS Group lifted their price target on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus upped their price objective on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.